Company News
Voyxact Posts +0.3 eGFR Slope, $78M Q2 Revenue
BTIG analysis of 24‑month VISIONARY trial shows Voyxact achieved an annualized eGFR slope of +0.3 mL/min/1.73 m², meeting KDIGO goal.
Compared with placebo, Voyxact improved eGFR by +4.5 mL/min/1.73 m
